The association of HIF-1α expression with clinicopathological significance in prostate cancer: a meta-analysis
Authors Huang M, Du H, Zhang L, Che H, Liang C
Received 6 January 2018
Accepted for publication 7 May 2018
Published 21 August 2018 Volume 2018:10 Pages 2809—2816
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Kenan Onel
Meng Huang,1,2 Hexi Du,3 Li Zhang,3 Hong Che,4 Chaozhao Liang3
1Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; 2Department of Ultrasound, The East District of First Affiliated Hospital of Anhui Medical University, The People’s Hospital of Feidong, Hefei, Anhui, China; 3Department of Urology, The First Affiliated Hospital of Anhui Medical University and Institute of Urology, Anhui Medical University, Hefei, Anhui, China; 4Department of Cardiology, The First Affiliated Hospital of Anhui Medical University and Institute of Urology, Anhui Medical University, Hefei, Anhui, China
Background: Hypoxia-inducible factor-1α (HIF-1α) plays an important role in tumor growth, invasion, and metastasis. The aim of this study was to perform a meta-analysis to explore the association of HIF-1α expression with clinicopathological significance in patients with prostate cancer (PCa).
Methods: A detailed literature search was made in PubMed, Embase, Cochrane Library, China Biology Medicine disc (CBM), and China National Knowledge Infrastructure (CNKI) up to August 21, 2017. Odds ratios (ORs) with 95% CIs were calculated to evaluate the strength of the correlations. Analysis of pooled data was performed using Review Manager 5.3 software.
Results: Eventually, 14 studies were identified and involved in this meta-analysis. The rate of HIF-1α protein expression was significantly higher in PCa than in nonmalignant prostate tissues (OR=12.01, 95% CI: 8.22–17.55, P<0.00001). Similar results were found in different subgroups. There were significant differences between HIF-1α expression and clinicopathological significance. The expression of HIF-1α protein was significantly associated with Gleason score (Gleason ≥7 vs Gleason <7: OR=3.58, 95% CI: 2.35–5.46, P<0.00001). The frequency of HIF-1α protein expression was significantly higher in T3–T4 stages than in T1–T2 stages of PCa (OR=3.70, 95% CI: 1.53–8.96, P=0.004). The expression of HIF-1α protein was significantly associated with the presence of lymph node and/or bone metastasis of PCa (metastasis positive vs negative: OR=7.07, 95% CI: 4.08–12.25, P<0.00001).
Conclusion: Taken together, our findings have demonstrated the certain associations of HIF-1α expression with an increased risk and clinicopathological significance in PCa patients, indicating that HIF-1α may serve as a valuable biomarker for diagnosing PCa and monitoring the progression.
Keywords: HIF-1α, prostate cancer, clinicopathological significance, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]